{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:24:56Z","timestamp":1762543496091,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Marcian\u00f2 et al. launched an alert in this journal about a possible association between medication-related osteonecrosis of the jaws (MRONJ) and cyclin-dependent kinase (CDK) 4\/6 inhibitors in breast cancer patients [...]<\/jats:p>","DOI":"10.3390\/ijerph181910143","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:39:20Z","timestamp":1632739160000},"page":"10143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4\/6 Inhibitors? A Word of Cautiousness. Comment on Marcian\u00f2 et al. Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509"],"prefix":"10.3390","volume":"18","author":[{"given":"Vittorio","family":"Fusco","sequence":"first","affiliation":[{"name":"Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera \u201cSS Antonio e Biagio e Cesare Arrigo\u201d, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9118-9237","authenticated-orcid":false,"given":"Manuela","family":"Alessio","sequence":"additional","affiliation":[{"name":"Study CoordinatorOncology Unit, Ospedale \u201cMichele e Pietro Ferrero\u201d, 12060 Verduno (CN), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Francesca","family":"Guglielmini","sequence":"additional","affiliation":[{"name":"Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera \u201cSS Antonio e Biagio e Cesare Arrigo\u201d, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Vincenti","sequence":"additional","affiliation":[{"name":"Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera \u201cSS Antonio e Biagio e Cesare Arrigo\u201d, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Fasciolo","sequence":"additional","affiliation":[{"name":"Maxillofacial Surgery Unit, Azienda Ospedaliera \u201cSS Antonio e Biagio e Cesare Arrigo\u201d, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Rossi","sequence":"additional","affiliation":[{"name":"Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera \u201cSS Antonio e Biagio e Cesare Arrigo\u201d, 15121 Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Marcian\u00f2, A., Guzzo, G.M., Peditto, M., Picone, A., and Oteri, G. (2020). Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249509"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Na\u00efve Patient: A Comprehensive Review of the Literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Folkmar","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2012007284","DOI":"10.1136\/bcr-2012-007284","article-title":"Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process","volume":"2012","author":"Bettini","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"djw002","DOI":"10.1093\/jnci\/djw002","article-title":"Regorafenib Also Can Cause Osteonecrosis of the Jaw","volume":"108","author":"Antonuzzo","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"djw155","DOI":"10.1093\/jnci\/djw155","article-title":"RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw","volume":"108","author":"Fusco","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"ref_9","first-page":"83","article-title":"Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence","volume":"11","author":"Gillespie","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Thanopoulou, E., Khader, L., Caira, M., Wardley, A., Ettl, J., Miglietta, F., Neven, P., and Guarneri, V. (2020). Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+\/HER2+) Breast Cancer: A Review of the Current Literature. Cancers, 12.","DOI":"10.3390\/cancers12113317"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-019-05133-y","article-title":"Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: An adjusted indirect analysis of randomized controlled trials","volume":"174","author":"Petrelli","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the Jaw in Patients with Metastatic Renal Cell Cancer Treated with Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"Loyson","year":"2018","journal-title":"Support Care Cancer."},{"key":"ref_16","unstructured":"(2021, August 08). FDA: Ibrance Full Prescription Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207103s008lbl.pdf."},{"key":"ref_17","unstructured":"(2021, August 08). FDA: Kisqali Highliths of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209092s000lbl.pdf."},{"key":"ref_18","unstructured":"(2021, August 08). FDA: Verzenio Highliths of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208855s000lbl.pdf."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/19\/10143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:05:44Z","timestamp":1760166344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/19\/10143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":18,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["ijerph181910143"],"URL":"https:\/\/doi.org\/10.3390\/ijerph181910143","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2021,9,27]]}}}